Clinuvel Pharmaceuticals Limited

ASX CUV.AX

Clinuvel Pharmaceuticals Limited Price to Sales Ratio (P/S) on January 14, 2025: 6.19

Clinuvel Pharmaceuticals Limited Price to Sales Ratio (P/S) is 6.19 on January 14, 2025, a -39.04% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Clinuvel Pharmaceuticals Limited 52-week high Price to Sales Ratio (P/S) is 10.37 on February 19, 2024, which is 67.56% above the current Price to Sales Ratio (P/S).
Clinuvel Pharmaceuticals Limited 52-week low Price to Sales Ratio (P/S) is 5.81 on January 12, 2025, which is -6.17% below the current Price to Sales Ratio (P/S).
Clinuvel Pharmaceuticals Limited average Price to Sales Ratio (P/S) for the last 52 weeks is 8.43.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

ASX: CUV.AX

Clinuvel Pharmaceuticals Limited

CEO	Dr. Philippe Jacques Wolgen M.B.A., M.D.
IPO Date	Feb. 11, 2001
Location	Australia
Headquarters	535 Bourke Street
Employees	16
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Key trends

Past 5 years